

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Cowart, et al.

Serial No.: 10/081,207

Filed: February 25, 2002

For: NOVEL AMINES AS HISTAMINE-3
RECEPTOR LIGANDS AND THEIR
THERAPEUTIC APPLICATIONS

Examiner: V. Balasubramanian

Group Art Unit: 1624

Case No.: 6791USO2

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: April 14, 2004

Tanya Parent 4/14/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in 37 C.F.R. §1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance, and is accompanied by the Petition fee of \$180.00 as specified under 37 C.F.R. §1.97(c). Applicant respectfully petitions and requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants hereby authorize the Commissioner to charge the appropriate Petition fee of \$180.00 to Deposit Account No. 01-0025. The Commissioner also is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered. A duplicate of this sheet is enclosed.


04/21/2004 WASFAW1 00000021 010025 10081207

01 FC:1806


180.00 DA

ABBOTT LABORATORIES
Customer No. 23492
Telephone: (847) 937-8272
Facsimile: (847) 938-2623

Respectfully submitted,
M. Cowart, et al.

A handwritten signature in black ink, appearing to read 'Portia Chen', is written over a horizontal line.

Portia Chen
Registration No. 44,075
Attorney for Applicants



DATE: April 14, 2004

SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 6791US02	SERIAL NO. 10/081,207
	APPLICANT(S) Cowart, et al.	
	FILING DATE February 25, 2002	GROUP 1624

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION


DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Bjenning et al., "Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat," Histamine Research In The New Mellennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, 22-25 November 2000, p. 449-450
C2	De Almeida et al., "Memory Facilitation by Histamine," Arch. Int. Pharmacodyn., 283:193-198 (1986).
C3	Delaunois et al., "Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H ₃ Receptors in Isolated Perfused Rabbit Lungs," European Journal Of Pharmacology, 277:243-250 (1995).
C4	Dimitriadou et al., "Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H ₃ -Receptor Modulation in Rat Lung and Spleen," Clinical Science, 87:151-163 (1994).
C5	Duméry et al., "Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat," Exp. Brain. Res., 67:61-69 (1987).
C6	Ellingboe et al., "Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole 2-Oxides," J. Med. Chem. 36:2485-2493 (1993)
C7	Fitzsimons et al., "Histamine Receptors Signalling in Epidermal Tumor Cell Lines With H-ras Gene Alterations," Inflamm. Res., 47, Supplement 1, S50-S51 (1998).
C8	Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus," Behavioural Brain Research, 66:41-44 (1995).
C9	Hatta et al., "Activation of Histamine H ₃ Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia ^{1,2} ," The Journal Of Pharmacology And Experimental Therapeutics, 283(2):494-500 (1997).
C10	Imamura et al., "Activation Of Histamine H ₃ -Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia," Circulation Research, 78(3):475-481 (1996).
C21	Imamura et al., "Histamine H ₃ -Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers," Circulation Research, 78(5):863-869 (1996).



C14	Kamei et al., "Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H ₁ -Blockers," Japan J. Pharmacol., 57:473-482 (1991).
C15	Leurs et al., "The Histamine H ₃ -Receptor: A Target For Developing New Drugs," Progress In Drug Research, 39:127-165 (1992).
C16	Leurs et al., "The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H ₃ Receptor," Progress In Drug Research, 45:107-165 (1995).
C17	Leurs et al., "Therapeutic Potential Of Histamine H ₃ Receptor Agonists And Antagonists," Trends In Pharm. Sci, 19:177-183 (1998).
C18	Levi et al., "Histamine H ₃ -Receptors: A New Frontier In Myocardial Ischemia," The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000).
C19	Lin et al., "Involvement Of Histaminergic Neurons In Arousal Mechanisms Demonstrated With H ₃ -Receptor Ligands In The Cat," Brain Research, 523:325-330 (1990).
C20	Matsubara et al., "UK-14,304, R(-) α -Methyl-Histamine And SMS 201-995 Block Plasma Protein Leakage Within Dura Mater By Prejunctional Mechanisms," European Journal Of Pharmacology, 224:145-150 (1992).
C21	Mazurkiewicz-Kwilecki et al., "Changes In The Regional Brain Histamine And Histidine Levels In Postmortem Brains Of Alzheimer Patients," Can. J. Physiol. Pharmacol, 67: 75-78 (1989).
C22	McLeod et al., "Histamine H ₃ Antagonists," Progress In Resp. Research 31:133-134 (2001)
C23	Monti et al., "Effects Of Selective Activation Or Blockade Of The Histamine H ₃ Receptor On Sleep And Wakefulness," European Journal Of Pharmacology, 205:283-287 (1991).
C24	Monti et al., "Sleep And Waking During Acute Histamine H ₃ Agonist BP2.94 Or H ₃ Antagonist Carboperamide (MR 16155) Administration In Rats," Neuropsychopharmacology, 15(1):31-35 (1996).
C25	Murakami et al., "AQ-0145, A Newly Developed Histamine H ₃ Antagonist, Decreased Seizure Susceptibility Of Electrically Induced Convulsions In Mice," Meth. Find. Exp. Clin. Pharmacol. 17(C):70-73 (1995)
C26	Onodera et al., "Neuropharmacology Of The Histaminergic Neuron System In The Brain And Its Relationship With Behavioral Disorders," Progress In Neurobiology, 42:685-702 (1994).
C27	Panula et al., "Histamine Neurons in Human Hypothalamus: Anatomy in Normal and Alzheimer Diseased Brains," Neuroscience 44(2):465-481 (1991)
C28	Panula et al., "Neuronal Histamine Deficit in Alzheimer's Disease," Neuroscience 82(4):993-997 (1998)
C29	Perez-Garcia et al., "Effects Of Histamine H ₃ Receptor Ligands In Experimental Models Of Anxiety And Depression," Psychopharmacology 142:215-220 (1999)
C30	Phillips et al., "Recent Advances In Histamine H ₃ Receptor Agents," Annual Reports In Medicinal Chemistry, 33:31-40 (1998).
C31	Rouleau, "Bioavailability, Antinociceptive And Antiinflammatory Properties Of BP 2-94, A Histamine H ₃ Receptor Agonist Prodrug," The Journal Of Pharmacology And Experimental Therapeutics, 281(3):1085-1094 (1997).
C32	Sakai et al., "Effects Of Thioperamide, A Histamine H ₃ Receptor Antagonist, On Locomotor Activity And Brain Histamine Content In Mast Cell-Deficient <u>W/W^v</u> Mice," Life Sciences, 48:2397-2404 (1991).
C33	Schwartz et al., "Histaminergic Transmission in the Mammalian Brain," Physiological Reviews 71(1):1-51 (1991)
C34	Schwartz et al., "Histamine," Psychopharmacology: The Fourth Generation Of Progress, 397-405 (1995).
C35	Shaywitz et al., "Dopaminergic But Not Noradrenergic Mediation Of Hyperactivity And Performance Deficits In The Developing Rat Pup," Psychopharmacology, 82:73-77 (1984).
C36	Szelag, "Role Of Histamine H ₃ -Receptors In The Proliferation Of Neoplastic Cells In Vitro," Med. Sci. Monit., 4(5):747-755 (1998).
C37	Tedford et al., "Cognition And Locomotor Activity In The Developing Rat: Comparisons Of Histamine H ₃ Receptor Antagonists And ADHD Therapeutics," Society For Neuroscience Abstr., 22:22 (1996).
C38	Tedford et al., "Pharmacological Characterization Of GT-2016, A Non-Thiourea-Containing Histamine H ₃ Receptor Antagonist: <i>In Vitro</i> And <i>In Vivo</i> Studies," The Journal Of Pharmacology And Experimental Therapeutics, 275(2):598-604 (1995).
C39	Wada et al., "Is The Histaminergic Neuron System A Regulatory Center For Whole-Brain Activity?," Trends In Neurosciences, 14(9):415-418 (1991).



C40	Yates et al., "Effects Of A Novel Histamine H ₃ Receptor Antagonist, GT-2394, On Food Intake And Weight Gain In Sprague-Dawley Rats," Abstracts, Society For Neuroscience, 102.10:219 (November 2000)
C41	Yokoyama et al., "Effect Of Thioperamide, A Histamine H ₃ Receptor Antagonist, On Electrically Induced Convulsions In Mice," Journal Of Pharmacology, 234:129-133 (1993).
C42	Yokoyama et al., "Histamine And Seizures Implications For The Treatment Of Epilepsy," CNS Drugs, 5(5):321-330 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)